Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

273 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-03-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy and safety of combined radiotherapy and hormone therapy and hormone therapy alone in the treatment of clinically locally advanced prostate cancer (T3-T4 or pT3 on biopsy, N0, M0).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

NCT04891731

Hormone Receptor-positive Breast Cancer

UNKNOWN

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410

Breast Cancer

COMPLETED PHASE3

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

NCT00171340

Bone Loss Breast Cancer

COMPLETED PHASE3

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

NCT02344550

Metastatic Breast Cancer

COMPLETED PHASE2

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

NCT01208441

Estrogen Receptor-positive Breast Cancer HER2-negative Breast Cancer Progesterone Receptor-positive Breast Cancer +2 more

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called leuprorelin SR. Leuprorelin SR is being tested to treat people who have prostate cancer. This study will look at the overall survival of people who take leuprorelin SR in addition to radiation therapy compared to those who take only leuprorelin SR.

The study will enroll approximately 273 patients. Participants will be randomly assigned to one of the two treatment groups.

* Combined Radiotherapy and Hormone Therapy
* Hormone Therapy alone. All participants will receive leuprorelin injection every 3 months and flutamide tablets thrice daily for first 30 days as part of hormone therapy. Participants randomized to combined radiotherapy and hormone therapy group, will also receive radiotherapy 70 +/- 4 Gy in 35 fractions at a rate of 5 fractions of 2 Gy per week.

This multi-center trial will be conducted in France and Tunisia. The overall time to participate in this study is 8 years. The scheduled duration of hormone therapy was 3 years in both arms, with an additional treatment-free follow-up period of 2 years i.e. a total follow-up period of 5 years. Post-protocol collection of information relative to survival will be performed after the end the 5-year follow-up period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Neoplasms, Locally Advanced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined Radiotherapy and Hormone Therapy

Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.

Group Type EXPERIMENTAL

Leuprorelin SR

Intervention Type DRUG

Leuprorelin SR injection

Radiotherapy

Intervention Type RADIATION

Radiotherapy 70 +/- 4 Gy

Flutamide

Intervention Type DRUG

Flutamide tablets

Hormone Therapy alone

Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.

Group Type ACTIVE_COMPARATOR

Leuprorelin SR

Intervention Type DRUG

Leuprorelin SR injection

Flutamide

Intervention Type DRUG

Flutamide tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Leuprorelin SR

Leuprorelin SR injection

Intervention Type DRUG

Radiotherapy

Radiotherapy 70 +/- 4 Gy

Intervention Type RADIATION

Flutamide

Flutamide tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ENANTONE SR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed locally advanced adenocarcinoma of the prostate, graded: T3 or T4 or pT3 on biopsies (presence of tumour tissue in periprostatic fat observed on biopsies), N0 (absence of metastatic), M0 (no distant metastases detectable on the following examinations: bone scan, chest x-ray, abdominal and pelvic ultrasound).
* Patient in whom the prostatic adenocarcinoma has received no prior treatment of any type, with the possible exception of transurethral resection due to obstructive symptoms.
* Patient with a Karnofsky index greater than or equal to (≥) 70.
* Patient aged under 80 years on the randomization date.
* Patient with a life expectancy of at least 7 years.
* Patient who, after having received clear information, gave his written consent to participate and cooperate in the study.
* Patient for whom a recent blood test (less than \[\<\] 2 months) has not revealed elevated transaminases ≥ 3 times the normal laboratory range.

Exclusion Criteria

* Patient incapable of understanding the information supplied concerning the study or of giving his consent, or having refused to sign the informed consent form,
* Patient for whom there is a risk that follow-up in compliance with the conditions stipulated by the protocol will not be possible,
* Patient having already received prior treatment for prostate cancer, excluding transurethral resection of the prostate to relieve obstruction,
* Patient having undergone surgical castration, or with a history of bilateral adrenalectomy or hypophysectomy,
* Patient having had another cancer within the previous 5 years (including carcinoma in situ of the bladder) excluding basocellular epithelioma or carcinoma in situ (other than in the bladder),
* Patient with lymph node or metastatic spread of the prostatic adenocarcinoma suspected on imaging,
* Patient with a non-controlled severe active disease,
* Patient with a contraindication to external prostatic radiotherapy,
* Patient receiving or having received another experimental treatment within 3 months prior to inclusion in the study,
* Patient with impaired liver function or elevated transaminases ≥3 times the normal laboratory range.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No